A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
WEBMar 19, 2024 · Obesity Novo Nordisk Eli Lilly GLP-1. If you’re feeling like overnight obesity became the indication du jour, you’re not alone. Novo Nordisk was granted approval for semaglutide to be marketed as...
Pfizer Provides Update on GLP-1-RA Clinical Development …
WEBJun 26, 2023 · Pfizer is continuing to advance the first full agonist oral GLP-1-RA candidate danuglipron toward late-state development; Danuglipron is the largest oral, small molecule GLP-1-RA clinical development program underway with over 1,400 participants enrolled for the treatment of obesity and T2DM
Beyond Ozempic: New GLP-1 drugs promise weight loss and …
WEBThere aren’t just GLP-1 drugs in the pipeline. On Thursday, ahead of the diabetes conference, Denmark-based biotech firm Zealand Pharma released data that showed a high dose of its experimental...
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 …
WEBJul 11, 2024 · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. …
What is the pipeline for future medications for obesity?
WEBFeb 1, 2024 · Understanding better the role of the entero-pancreatic hormones in the regulation of feeding, appetite and glycaemia (Fig. 1) has led to the development of the glucagon-like peptide-1...
- [PDF]
Pfizer Pipeline
WEBFeb 8, 2022 · Pfizer Pipeline Snapshot as of November 2, 2021. Pipeline represents progress of R&D programs as of November 2, 2021. 13 programs advanced or are new. 16 programs discontinued since last update. Included are 59 NMEs, 35 additional indications. Recent Approvals.
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist ...
WEBNEW YORK, December 01, 2023--Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist...
New developments in the prospects for GLP‐1 therapy
WEBFeb 2, 2022 · The glucagon‐like peptide‐1 (GLP‐1) receptor agonist, semaglutide, has recently been confirmed as the most efficacious weight‐loss drug in clinical use (Wilding et al., 2021), which highlights a major success in the clinical exploitation of the humble 30 amino acid incretin hormone, GLP‐1.
Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and
WEBThis article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM. Keywords: G protein-coupled receptor 119 agonist; diabetes mellitus; gastric inhibitory polypeptide; glucagon receptor agonist; glucagon-like peptide-1 receptor agonist.
AstraZeneca Pays $185M to Add Oral GLP-1 Drug Candidate to Pipeline
WEBNov 9, 2023 · AstraZeneca Pays $185M to Add Oral GLP-1 Drug Candidate to Pipeline. AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based...